An interesting figure in this month’s ASN Kidney News details the quarterly earnings for three major dialysis companies in the U.S.: DaVita, Dialysis Corporation of America (DCA), and Fresenius.
Also included in the figure (not shown here) is the “revenue per treatment”–that is, how much profit each company obtains from the average patient’s dialysis run. For example, Fresenius reported a revenue per treatment of $348 for the 3rd quarter of 2009. I’m not sure how they arrive at these numbers, but you can do a quick calculation to figure out how much a single patient dialyzing on the standard 3x/week schedule is worth to the company on a yearly basis: $348/treatment x 3 treatments/week x 52 weeks/year = $54,288.00/year. Like it or not, dialysis is also a business.
